Actively Recruiting
A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)
Led by Beijing Institute of Heart, Lung and Blood Vessel Diseases · Updated on 2022-04-12
1000
Participants Needed
1
Research Sites
569 weeks
Total Duration
On this page
Sponsors
B
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Lead Sponsor
S
Shanghai Zhongshan Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Takayasu arteritis is a chronic vasculitis mainly involving the aorta and its main branches such as the brachiocephalic, carotid, subclavian, vertebral, and renal arteries, as well as the coronary and pulmonary arteries. Inflammation causes segments of the vessels to become narrowed, blocked, or even stretched, possibly resulting in aneurysms. The disease is very rare but most commonly occurs in young Asian women. However, there is a considerable lack of understanding of the disease mechanism of Takayasu arteritis. Initially, the disease remains clinically silent (or remains undetected) until the patients present with vascular occlusion. Additionally, many individuals with Takayasu arteritis, however, have no apparent symptoms despite disease activity. Therefore, biomarkers for diagnosis and monitor disease activity in individuals with Takayasu arteritis are needed. In this study, the investigators therefore to use different methods to identify new biomarkers for diagnosing or monitoring the disease activity in individuals with Takayasu arteritis. These biomarkers may provide valuable insights into the underlying biochemical processes and aid the understanding of the pathophysiology of this disease.
CONDITIONS
Official Title
A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects who meet the American College of Rheumatology 1990 classification criteria for Takayasu arteritis by meeting more than 3 of 6 specific clinical and imaging criteria
- Age of onset 40 years or younger
- Presence of claudication in upper or lower limbs
- Decreased pulse in one or both brachial arteries
- Difference of 10 mmHg or more in systolic blood pressure between arms
- Bruit heard over subclavian arteries or aorta
- Imaging evidence (MRA or CTA) showing stenosis or occlusion of a branch of the aorta
- Subjects with initial suspicion of Takayasu arteritis or needing disease activity assessment enrolled prospectively
You will not qualify if you...
- Arteriographic lesions explained entirely by atherosclerosis
- Having other autoimmune diseases such as ANCA-associated vasculitis or systemic lupus erythematosus
- Diagnosis of Cogan's syndrome
- Diagnosis of Behcet's disease
- Having any serious acute or chronic infection
- Having giant cell arteritis or other infectious large vessel vasculitis if aged 50 or older
- Patients without imaging studies
- Patients with confirmed other autoimmune diseases in prospective group
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
Y
Yuan WANG, PhD
CONTACT
F
Fengjuan LI, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here